Ironwood Pharmaceuticals, Inc.IRWDNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, above historical average.
Left:
||||
Year-over-year operating income growth rate
Latest
66.55%
↑ 177% above average
Average (39q)
-85.89%
Historical baseline
Range
High:255.70%
Low:-1902.32%
CAGR
-0.4%
Modest growth trend
| Period | Value |
|---|---|
| Q3 2025 | 66.55% |
| Q2 2025 | 255.70% |
| Q1 2025 | -192.43% |
| Q4 2024 | 22.84% |
| Q3 2024 | 2.64% |
| Q2 2024 | 126.65% |
| Q1 2024 | -70.68% |
| Q4 2023 | -22.67% |
| Q3 2023 | 104.49% |
| Q2 2023 | -1902.32% |
| Q1 2023 | -12.09% |
| Q4 2022 | -0.16% |
| Q3 2022 | 23.03% |
| Q2 2022 | -3.79% |
| Q1 2022 | 2.22% |
| Q4 2021 | -13.16% |
| Q3 2021 | 0.11% |
| Q2 2021 | 43.39% |
| Q1 2021 | -11.65% |
| Q4 2020 | 12.64% |
| Q3 2020 | 39.44% |
| Q2 2020 | 147.32% |
| Q1 2020 | -73.33% |
| Q4 2019 | -24.73% |
| Q3 2019 | 205.36% |
| Q2 2019 | 139.68% |
| Q1 2019 | -1006.96% |
| Q4 2018 | 103.55% |
| Q3 2018 | -323.59% |
| Q2 2018 | -11.30% |
| Q1 2018 | -257.56% |
| Q4 2017 | 217.14% |
| Q3 2017 | 52.61% |
| Q2 2017 | -3.29% |
| Q1 2017 | -530.24% |
| Q4 2016 | 77.73% |
| Q3 2016 | -84.70% |
| Q2 2016 | -678.20% |
| Q1 2016 | 66.23% |
| Q4 2015 | 77.75% |